Digital healthcare company Ro offers prescriptions for hair loss, menopause, and sexual health.
Now it's becoming the first online pharmacy to offer FDA-approved allergy treatments. The segment includes up to 50 million people in the U.S. who suffer from the chronic condition.
"If you look at a condition like allergies, it's perfect for our platform," Dr. Melynda Barnes, vice president of medical affairs, told Cheddar. "We have the capability of doing everything from diagnosis to delivery of treatment."
Ro is the parent company behind digital health clinics Roman (for men) and Rory (for women) as well as a service for dealing with nicotine addiction called Zero.
Its platforms will offer allergy medicine to patients, which furthers the startup's goal of serving as a one-stop-shop for basic health needs.
"Our goal at Ro is to be a patient's first call, and for us, that means moving toward a primary care practice," Barnes said.
Though many allergy treatments are available over the counter, research shows that 80 percent of people choose the incorrect medication on their own. Using telehealth options for quick access to a certified physician, Ro hopes to take out the guesswork for patients.
"I don't think we'll ever replace in-person care," Barnes said. "In fact, at Ro, our goal is to be a complement to our in-person colleagues."
But that hasn't stopped Ro from expanding into other aspects of personal healthcare, including spreading knowledge to patients online.
The company recently launched Health Guide, a medical handbook that is 30 percent written by doctors and 100 reviewed by them. Ro is promoting the service as a competitor to WebMD.
"Right now, we know that physicians feel like they can spend more time with really sick patients if they can take care of healthier patients through an alternative health care model like telemedicine," Barnes said.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Scott Trench, host of the BiggerPockets Money Podcast, explores how recent rate cuts, high borrowing costs, and mortgage rates are reshaping U.S. real estate.
A look into how disruption, AI, and global economic trends are transforming the modern supply chain with Jeremy Jansen, Head of Supply Chain at Wells Fargo.
Delta CSO Amelia DeLuca reveals at the Fast Co. Innovation Festival how tech, sustainable aviation fuel, and smart operations are revolutionizing air travel.
Chipmaker Nvidia will invest $100 billion in OpenAI as part of a partnership that will add at least 10 gigawatts of Nvidia AI data centers to ramp up the computing power for the owner of the artificial intelligence chatbot ChatGPT.
